Publicaciones en colaboración con investigadores/as de Academic Medical Center (208)

2024

  1. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  2. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

  3. High prevalence of venous thrombotic events in Cushing’s syndrome: data from ERCUSYN and details in relation to surgery

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 75-85

  4. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

  5. The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial

    Journal of Critical Care, Vol. 79

  6. The science of micronutrients in clinical practice – Report on the ESPEN symposium

    Clinical Nutrition

2023

  1. A European-Japanese study on peach allergy: IgE to Pru p 7 associates with severity

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 9, pp. 2497-2509

  2. A Travel Through Time: Percutaneous Management of Degenerated Coronary Saphenous Vein Grafts

    JACC: Case Reports, Vol. 10

  3. Abnormal physiological findings after FFR-based revascularisation deferral are associated with worse prognosis in women

    Scientific Reports, Vol. 13, Núm. 1

  4. Changes in microvascular resistance following percutaneous coronary intervention - From the ILIAS global registry

    International Journal of Cardiology, Vol. 392

  5. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  6. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  7. Development of artificial intelligence tools for invasive Doppler-based coronary microvascular assessment

    European Heart Journal - Digital Health, Vol. 4, Núm. 4, pp. 291-301

  8. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    The Lancet Regional Health - Europe, Vol. 33

  9. EAACI guidelines on the diagnosis of IgE-mediated food allergy

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 12, pp. 3057-3076

  10. ESPEN guideline on chronic intestinal failure in adults – Update 2023

    Clinical Nutrition, Vol. 42, Núm. 10, pp. 1940-2021

  11. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  12. Impact of core laboratory assessment on treatment decisions and clinical outcomes using combined fractional flow reserve and coronary flow reserve measurements – DEFINE-FLOW core laboratory sub-study

    International Journal of Cardiology, Vol. 377, pp. 9-16

  13. Impact of stenosis resistance and coronary flow capacity on fractional flow reserve and instantaneous wave-free ratio discordance: a combined analysis of DEFINE-FLOW and IDEAL

    Netherlands Heart Journal, Vol. 31, Núm. 11, pp. 434-443

  14. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer

    Cancer Science, Vol. 114, Núm. 3, pp. 1026-1036